Results 51 to 60 of about 11,985 (168)

Tocilizumab for severe and refractory mucous membrane pemphigoid

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Elevated IL‐6 levels identified in mucous membrane pemphigoid support IL‐6 blockade, with tocilizumab demonstrating clinical benefit in nine patients with severe and refractory mucous membrane pemphigoid. Abstract Background Mucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease involving mucous membranes with a potentially ...
Billal Tedbirt   +20 more
wiley   +1 more source

Giant cell arteritis as a cause of fever of unclear genesis in the elderly

open access: yesТерапевтический архив, 2014
The paper describes a case of giant cell arteritis whose leading clinical sign is long-term fever. It discusses current approaches to diagnosing giant cell arteritis.
S V Guliaev   +4 more
doaj  

The impact of systemic long‐term medications for the development of age‐related macular degeneration

open access: yesActa Ophthalmologica, Volume 104, Issue 6, Page 674-681, September 2026.
Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä   +3 more
wiley   +1 more source

Fatal Aortic Dissection in a Patient with Giant Cell Arteritis: A Case Report and Review of the Literature

open access: yesCase Reports in Vascular Medicine, 2013
Giant cell arteritis may lead to catastrophic, large-vessel complications from chronic vascular wall inflammation without prompt diagnosis and treatment.
Anjeli K. Nayar   +3 more
doaj   +1 more source

Ultrasound, PET/CT or temporal artery biopsy for giant cell arteritis? A prospective diagnostic accuracy study (the GAME‐study)

open access: yesActa Ophthalmologica, Volume 104, Issue 6, Page e695-e708, September 2026.
Abstract Purpose To investigate the diagnostic performance of ultrasound, 2‐deoxy‐2‐[18F]fluoro‐D‐glucose positron emission tomography/computed tomography (2‐[18F]FDG PET/CT) and temporal artery biopsy (TAB) in giant cell arteritis (GCA). Methods This was a prospective single‐centre diagnostic accuracy study (ClinicalTrials.gov NCT05248906).
Michael S. Hansen   +10 more
wiley   +1 more source

Prescribing of Medication to Prevent Glucocorticoid Harms in Patients With Polymyalgia Rheumatica: A Cross‐Sectional Study and Two Emulated Target Trials in the Clinical Practice Research Datalink Aurum

open access: yesArthritis &Rheumatology, Volume 78, Issue 8, Page 1731-1740, August 2026.
Objective Polymyalgia rheumatica (PMR) is a common indication for long‐term glucocorticoid (GC) treatment. Bone‐protective and gastroprotective medications are recommended for those at high risk of adverse events from GCs, but no trials have evaluated their effectiveness in PMR.
Helen Twohig   +5 more
wiley   +1 more source

Painful Bilateral Necrosis of the Scalp

open access: yes
JEADV Clinical Practice, EarlyView.
Zoé Dumesnil   +6 more
wiley   +1 more source

Thunderclap Headache in a Patient With Giant Cell Arteritis: Consider Aortic Dissection

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Thunderclap is a rare but important manifestation of type A aortic dissection and may occur as the sole presenting feature in patients who do not experience chest pain.
Alice Lee   +4 more
wiley   +1 more source

Aortitis in Extracranial Giant Cell Arteritis: Do Not Lose Sight of the Patient

open access: yesAnnals of Internal Medicine: Clinical Cases
Giant cell arteritis is the most common systemic vasculitis. This case highlights aortic dissection as a potentially life-threatening complication of giant cell arteritis, in most instances occurring as very late event years or even decades after initial
Lilly J.U. Reik   +3 more
doaj   +1 more source

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

open access: yesAllergy, Volume 81, Issue 8, Page 2775-2791, August 2026.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy